Comunicados de prensa de Rhelion Life Sciences

Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.Fila…

Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.Toronto, Ontario--(Newsfile Corp. - October…

Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a cond…

Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a Phase 2 trial of psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence.Toront…

Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to suppor…

A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual pr…

Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and…

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.Toro…

Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innov…

Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Ps…

Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for cl…

Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovati…

A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the stand…

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in pe…

Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovatio…

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment…

Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (OTCQB: TRUFF) (FSE: 4YX) ("Rhelion" or the "Company") is pleased to announce that it has completed its co…